Drug Resistance of Acinetobacter in Selected Hospitals
Novelty in Biomedicine,
Vol. 3 No. 3 (2015),
22 July 2015
,
Page 103-110
https://doi.org/10.22037/nbm.v3i3.7976
Abstract
Background: Nowadays, nosocomial infection with multidrug-resistant Acinetobacter is an important problem in the world, which is facing wide spectrum antibiotics and hence has become resistant.Materials and Methods: In this study, positive cultures of Acinetobacter from one hundred clinical samples in seven hospitals from Tehran during 2012-2013 were collected for checking antibiotic susceptibility. Samples test with Ceftazidim, Cefepime, Amikacine and Imipenem by E-test and for Tazocin, Colistin and Tigecycline was performed with disk diffusion method.
Results: For Colistin 10 samples, and for Tazocin, 40 samples were performed by E-test method. Then boumannii species of bacteria and non-baumannii Acinetobacter were separated by PCR and antibiotic susceptibility testing was performed on them. 89% of Acinetobacter samples were boumannii species, which was isolated from respiratory secretions at ICU.
Conclusion: Boumannii and non-boumannii species of bacteria with a high percentage were resistant to Ceftazidim, Amikacine, Cefepime, Tazocin and Imipenem. All baumannii and non-boumannii Acinetobacter were sensitive to Colistin, were only 75% sensitive to Tigecycline, which is a new glycylcycline. Colistin and Tazocin results in samples limited to the E-test method were similar with disk diffusion.
- Acinetobacter
- Drug Resistance
How to Cite
References
Hortzell J, Kim A, Kortepeter M, Moran K. Acinetobacter Pneumonia: a review. MedGenMed. 2007; 9(3):4.
Kishk R, Mandour M, Farghaly R, Ibrahim A, Nemr N. Pattern of Blood Stream Infections within Neonatal Intensive Care Unit, Suez Canal University Hospital, Ismailia, Egypt, Int J Microbiol. 2014;2014:276873.
Schofer J and Mangino J. Multidrug-Resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg Infect Dis. 2008;14(3):512–4.
Abbo A, Novon–Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug- resistant Acinetobacter baumannii. Emerg Infect Dis. 2005;11(1):22–9.
Beceiro A, Tomás M, Bou G. Antimicrobial Resistance and Virulence: a Successful or Deleterious Association in the Bacterial World? Clin Microbiol Rev. 2013;26(2):185–230.
Reddy T, Chopra T, Marchaim D, Pogue JM, Alangaden G, Salimnia H et al. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother. 2010;54(5):2235-8.
Halachev MR, Chan JZ, Constantinidou CI, Cumley N, Bradley C, Smith-Banks M, et al. Genomic epidemiology of a protracted hospital outbreak caused by multidrug-resistant Acinetobacter baumannii in Birmingham, England. Genome Med. 2014;6(11):70.
Prashanth K, Badrinath S. Nosocomial infections due to Acinetobacter species: Clinical findings, risk and prognostic factors. Indian J Med Microbiol. 2006;24(1):39-44.
Yadegarinia D, Abedy Sh, Gachkar L, Rahmati Roodsari S. Prevalence and drug resistance of Acinetobacter baoumanii in ICU of teaching hospital. J Appl Environ Biol Sci. 2013;3(9):22-7.
Villegas MV, Kattan JN, Correa A, Lolans K, Guzman AM, Woodford N,et al. Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals. Antimicrob Agents Chemother. 2007;51(6):2001-4.
Chen HP1, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, et al. Predictors of mortality in Acinetobacter baumannii bacteria. Journal Microbial Immunol infect1. 2005;38(2):127-36.
Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, et al. Evolution of antimicrobial resistance among pseudomonas aeruginosu, Acinetobacter baumannii and klebsiella pneumoniae in Brooklyn.NY. J Antimicrob Chemother. 2007;60(1):78-82.
Halaby T, Al Naiemi N, Kluytmans J, Palen J, Vandenbroucke-Grauls CM. Emergence of Colistin resistance in Entrobacteriaceae after the introduction of selective tract decontamination in an intensive care unit. Antimicrob. Agents chemother. 2013;57(7):3224-9.
Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and invitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother. 2002;49(3):479-87.
Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C, et al. Antibiograms of multidrug – Resistant clinical Acinetobacter baumannii promising therapeutic options for treatment of infection with colistin – Resistant strains. Clin Infect Dis. 2007;45(5):594-8.
Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E,et al. An outbreak of multidrug Resistant Acinetobacter baumannii- calcoaceticus complex infection in the US military Health care system Associated with military operation in Iraq. Clin Infect Dis. 2007;44(12):1577-84.
Hawley JS, Murray CK, Jorgensen JH. Colistin Heteroresistance in Acinetobacter and its Association with previous colistin therapy. Antimicrobial Agents and chemotherapy. Antimicrob Agents Chemother. 2008;52(1):351-2.
Capone A, D'Arezzo S, Visca P, Petrosillo N, In vitro activity of tigecycline against multidrug resistant Acinetobacter baumannii. J Antimicrob Chemother. 2008;62(2):422-3.
Curcio D, Fernández F. Acinetobacter spp. Suscebtibility to Tigecycline: a worldwide perspective. J Antimicrob Chemother. 2007;60(2):449-50.
Casal M, Rodríguez F, Johnson B, Garduno E, Tubau F, de Lejarazu RO, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline- non- susceptible Acinetobacter spp. J Antimicrob Chemother. 2009;64(1):69-72.
Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acineto bacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60(5).
Arroyo LA, García-Curiel A, Pachón-Ibañez ME, Llanos AC, Ruiz M, Pachón J, et al. Reliability of the E-test method for Detection of colistin Resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol. 2005;43(2):903-5.
Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007;60(2):317-22.
Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and Distribution of bla oxa Genes among Acinetobacter spp. Isolated from patients at Tehran Hospitals. Jpn. J infects Dis. 2008;61:274-8.
Ekrami A, Kalantar E. Bacterial infections in burn patients at a burn hospital in Iran. Indian J Med Res. 2007;126:541-4.
Bayram A, Balci I. Patterns of antimicrobial resistance in a surgical intensive care unit of a university hospital in Turkey. BMC Infect Dis. 2006;25(6):155.
Petersen K, Riddle MS, Danko JR, Blazes DL, Hayden R, Tasker SA et al. Trauma- related infections in Battlefield casualties From Iraq. Ann surg. Ann Surg. 2007;245(5):803-11.
Cunha BA. Optimal Therapy for Multidrug-Resistant Acinetobacter baumannii Emerging infectious Diseases. Emerg Infect Dis. 2010;16(1):170.
Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter baoumannii: From bench to bedside. World J Clin Cases. 2014;2(12):787-814.
- Abstract Viewed: 639 times
- PDF Downloaded: 584 times